OncoCyte Corporation (OCX) Tops Q1 EPS by 12c

OncoCyte Corporation (NASDAQ: OCX) reported Q1 EPS of $0.04, $0.12 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $457 thousand.

For earnings history and earnings-related data on OncoCyte Corporation (OCX) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c
• ArriVent BioPharma, Inc. (AVBP) Misses Q2 EPS by 13c